Jasper Q3 net loss $18.7M; BEACON investigation finds no drug quality issues; cash $50.9M

Jasper Therapeutics, Inc.

2025-Q3 EPS reported -$4.18

Net loss of $18.7M ($1.13 per share); R&D expense $14.4M, G&A $4.8M.
Cash $50.9M at Sep 30; completed $30M stock/warrant offering extending runway into H1 2026.
BEACON investigation: no drug substance or product issues; focus now on clinical site processes.
Final BEACON conclusions expected Q4 2025; additional data from BEACON and OLE in H1 Q1 2026 for Phase 2b dose selection.
Initial data from ETESIAN asthma study planned for Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.